DeepMed Research

Jiangsu Hengrui Medicine Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: SHR7390
Biological: SHR-1210
Drug: SHR3162

First Posted Date: 2017-06-09

Last Posted Date: 2022-09-01

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 31

Registration Number: NCT03182673

Locations: 🇨🇳
The Cancer Center,Sun Yat-sen University, Guangzhou, Guangdong, China

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment

Phase 1

Conditions: Hepatic Impairment

Interventions: Drug: SHR3824

First Posted Date: 2017-05-19

Last Posted Date: 2017-05-19

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT03160014

Locations: 🇨🇳
XiJing Hospital, XiAn, Shanxi, China

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient

Phase 1

Conditions: Renal Insufficiency,Type 2 Diabetes

Interventions: Drug: SHR3824

First Posted Date: 2017-05-19

Last Posted Date: 2017-05-19

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT03159832

Locations: 🇨🇳
Chinese people's liberation army general hospital of Chengdu military area, Chengdu, Sichuan, China

Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes

Phase 3

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: SHR3824
Drug: Placebo

First Posted Date: 2017-05-18

Last Posted Date: 2017-05-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 450

Registration Number: NCT03159052

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, China

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Hodgkin Lymphoma, Adult

Interventions: Drug: SHR-1210

First Posted Date: 2017-05-16

Last Posted Date: 2024-02-01

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 75

Registration Number: NCT03155425

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Phase 3

Completed

Conditions: Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Respiratory Tract Disease
Thoracic Neoplasms
Lung Diseases
Neoplasms by Site
Neoplasm, Bronchial
Carcinoma, Bronchogenic

Interventions: Biological: SHR-1210
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2017-05-01

Last Posted Date: 2020-06-09

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 419

Registration Number: NCT03134872

Locations: 🇨🇳
Tongji University, Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout

Phase 1

Completed

Conditions: Gout

Interventions: Drug: Colchicine
Drug: Febuxostat
Drug: SHR4640

First Posted Date: 2017-04-27

Last Posted Date: 2019-08-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 15

Registration Number: NCT03131583

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Phase 1

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: SHR-1210
Drug: Gemcitabine
Drug: cis-platinum

First Posted Date: 2017-04-20

Last Posted Date: 2022-07-12

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 23

Registration Number: NCT03121716

Locations: 🇨🇳
Jiangsu Hengrui, Shanghai, China

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3

Completed

Conditions: Esophageal Carcinoma

Interventions: Biological: camrelizumab
Drug: Docetaxel
Drug: Irinotecan

First Posted Date: 2017-04-04

Last Posted Date: 2024-01-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 457

Registration Number: NCT03099382

Locations: 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Phase 2

Completed

Conditions: Advanced Primary Liver Cancer
Advanced Biliary Tract Carcinoma

Interventions: Biological: SHR-1210
Drug: FOLFOX4
Drug: Apatinib
Drug: GEMOX

First Posted Date: 2017-03-28

Last Posted Date: 2023-02-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 157

Registration Number: NCT03092895

Locations: 🇨🇳
Cancer Hospital of Henan province, Zhengzhou, Henan, China
🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy